Amarin’s REDUCE-IT Clinical Study Now Positioned to be Next Large Cardiovascular Outcomes Study to Report Results
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
